Latest

Jan 29, 2018
Outlining the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Jan 19, 2018
Darcee Strube offers an overview of the key issues and progress made in dermatology biologics.
Jan 18, 2018
Rachel Howard makes the case for pharmaceutical companies to include the developing world front and centre in their vision.
Jan 11, 2018
Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.
Jan 10, 2018
Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.
Dec 11, 2017
Pharmaceutical Executive
Groundbreaking treatment approaches call for innovative commercialization strategies.
Dec 10, 2017
Pharmaceutical Executive
How Ruud Dobber is steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
Dec 01, 2017
The Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.
Nov 30, 2017
Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
Nov 10, 2017
Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.
native1_300x100
lorem ipsum